vedolizumab,infliximab,ustekinumab
janssen,takeda
['infliximab', 'inflammatory,bowel', 'ibd', ' vedo', 'ustekinumab', 'vedolizumab', 'marker ']
 presents best of 2022 articles from apt at #aibd2022 could differences in the microbiome predict therapy responses? how can we implement this in our future practices as we think about therapeutics for our ibd patients? 